The existing biologically targeted agents aim at key cytokines, mainly TNF and the IL-6 family (179, 180), and have been reported to reduce disease activity and achieve partial remission of RA, but they may cause undesired immune suppression. The gene discussed is IL6; the disease is rheumatoid arthritis.